Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

By afschroeder • December 1, 2025

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025 Nov;10(11):105858. doi: 10.1016/j.esmoop.2025.105858. Epub 2025 Oct 17. PMID: 41320342.

Tags: CDK4/6 inhibitor, early breast cancer, Hematology/Oncology, HR positive/HER2 negative, NATALEE, Publications, ribociclib

Related Posts

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer

Park W, Kasi A, Spira AI, Paz-Ares Rodríguez L, Herzberg BO, Pelster MS, Tolcher AW, Kuboki Y, Kitano S, Shoji H, Wang JS, Berlin JD,[...]

The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer

Cecchini M, Han SW, Lee S, Lee KW, Kopetz S, Mizrahi J, Hong YS, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao[...]

Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]